Literature DB >> 22571879

Pre-treatment waking cortisol response and vulnerability to interferon α induced depression.

Jessica Eccles1, Camille Lallemant, Farrah Mushtaq, Matthew Greenwood, Majella Keller, Bruno Golding, Jeremy Tibble, Inam Haq, Richard Whale.   

Abstract

Depressive disorder is a common consequence of interferon α treatment. An understanding of the aetiological processes involved is evolving. HPA axis abnormalities are clearly described in community depressive disorder and represent vulnerability to depression development. We explored whether pre-treatment HPA axis abnormalities influence depression emergence during interferon α treatment. We examined waking HPA axis response via salivary cortisol sampling in 44 non-depressed, chronic hepatitis C infected patients due to commence standard interferon α treatment. Hamilton depression scales and the structured clinical interview for DSM-IV major depressive disorder status were administered monthly during treatment. Major depressive disorder developed in 26 of 44 subjects during interferon-α treatment. The pre-treatment waking cortisol response over 1h was significantly greater in the subsequent switch to depression group (F=4.23, p=0.046). The waking cortisol response pre-treatment with interferon α appears greater in those subsequently switching to depressive disorder during treatment. This waking response may join other vulnerability factors for depression emergence in this group. This model could prove a valuable tool in understanding non-iatrogenic depressive disorder in the general population and notably the role of cytokines.
Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571879     DOI: 10.1016/j.euroneuro.2012.03.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  3 in total

1.  Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C.

Authors:  Renata Fialho; Alison Burridge; Marco Pereira; Majella Keller; Alexandra File; Jeremy Tibble; Richard Whale
Journal:  Psychopharmacology (Berl)       Date:  2015-05-15       Impact factor: 4.530

2.  Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin.

Authors:  Mary Ellen Dias Barbosa; Ana Luiza Zaninotto; Daniel Ferraz de Campos Mazo; Mario Guimarães Pessoa; Cláudia Pinto Marques Souza de Oliveira; Flair José Carrilho; Alberto Queiroz Farias
Journal:  BMC Gastroenterol       Date:  2017-11-25       Impact factor: 3.067

3.  Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis.

Authors:  Andreas Baranyi; Andreas Meinitzer; Robert J Breitenecker; Omid Amouzadeh-Ghadikolai; Rudolf Stauber; Hans-Bernd Rothenhäusler
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.